Android Apple

GSK Sees Positive Results in Trial of Combination RSV, Shingles Vaccine

By MarketWatch   |   3 months ago
GSK Sees Positive Results in Trial of Combination RSV, Shingles Vaccine

GSK's successful late-stage trial combined a respiratory syncytial virus vaccine with a shingles vaccine for adults 50+. The study showed a positive immune response and tolerable side effects, leading to potential regulatory approval and publication.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.